INOVIQ Ltd Annual Report 2022

3 Annual Report 2022 Bolstering our teamwith key appointments During the year we made several key appointments to the team in order to accelerate our product development and commercialisation strategies. We were extremely fortunate to secure world-leading medical researcher Dr Greg Rice to the position of Chief Scientific Officer and since joining in September 2021, he has been instrumental in driving our R&D programs into the clinical development and commercialisation phase. We also appointed Dr Rocco Iannello to the newly created position of Business Development and Licensing Director, with his expertise already proving invaluable to our IP commercialisation, licensing agreements and EXO-NET roll-out efforts. Looking ahead... While market conditions have been difficult and the journey of a biotech company is never straightforward, we evolved our business and made significant progress this year. With our proprietary technologies and strong development pipeline, current funding, and high-calibre people, INOVIQ is well positioned to advance our multi-product exosome capture tool and precision diagnostics pipeline towards key development and commercialisation milestones in financial year 2023. We expect our SubB2M-based tests for breast and ovarian cancer monitoring to commence clinical studies by December 2022 and be launch-ready as laboratory developed tests in the second half of calendar year 2023. We are also focused on developing new EXO-NET exosome isolation products for research applications and expanding EXO-NET collaborations for development of novel exosome-based diagnostic applications. Additionally, we look forward to progressing the development of the exosome-based ovarian cancer screening test with The University of Queensland. In closing, we would like to thank the INOVIQ team for their unwavering dedication to the Company’s ultimate ambition of improving patient health outcomes in areas of important unmet needs. We also sincerely thank shareholders for your continued support and faith in our company. Dr Geoff Cumming Chairman Dr Leearne Hinch CEO

RkJQdWJsaXNoZXIy MjE2NDg3